Jazz Pharmaceuticals plc

Symbol: JAZZ

NASDAQ

124.79

USD

Market price today

  • 17.0643

    P/E Ratio

  • 0.0380

    PEG Ratio

  • 7.78B

    MRK Cap

  • 0.00%

    DIV Yield

Jazz Pharmaceuticals plc (JAZZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.85%

Operating Profit Margin

0.17%

Net Profit Margin

0.11%

Return on Assets

0.04%

Return on Equity

0.12%

Return on Capital Employed

0.07%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Bruce C. Cozadd
Full-time employees:2800
City:Dublin
Address:Waterloo Exchange
IPO:2007-06-01
CIK:0001232524

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

General Outlook

When we look at how much money they make before expenses, they keep 0.847% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.172%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.108%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.036% return, is a testament to Jazz Pharmaceuticals plc's adeptness in optimizing resource deployment. Jazz Pharmaceuticals plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.118%. Furthermore, the proficiency of Jazz Pharmaceuticals plc in capital utilization is underscored by a remarkable 0.067% return on capital employed.

Stock Prices

Jazz Pharmaceuticals plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $112.19, while its low point bottomed out at $110.01. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Jazz Pharmaceuticals plc's stock market.

Liquidity Ratios

Analyzing JAZZ liquidity ratios reveals its financial health of the firm. The current ratio of 212.40% gauges short-term asset coverage for liabilities. The quick ratio (151.76%) assesses immediate liquidity, while the cash ratio (78.50%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio212.40%
Quick Ratio151.76%
Cash Ratio78.50%

Profitability Ratios

JAZZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 7.77% underscores its earnings before tax deductions. The effective tax rate stands at -40.25%, revealing its tax efficiency. The net income per EBT, 139.24%, and the EBT per EBIT, 45.26%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 17.17%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin7.77%
Effective Tax Rate-40.25%
Net Income per EBT139.24%
EBT per EBIT45.26%
EBIT per Revenue17.17%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.12, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 543.25% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding152
Days of Inventory Outstanding371
Operating Cycle438.35
Days of Payables Outstanding64
Cash Conversion Cycle374
Receivables Turnover5.43
Payables Turnover5.71
Inventory Turnover0.98
Fixed Asset Turnover16.32
Asset Turnover0.34

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 17.45, and free cash flow per share, 17.05, depict cash generation on a per-share basis. The cash per share value, 25.99, showcases liquidity position. A payout ratio of 0.27 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.28, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share17.45
Free Cash Flow per Share17.05
Cash per Share25.99
Payout Ratio0.27
Operating Cash Flow Sales Ratio0.28
Free Cash Flow to Operating Cash Flow Ratio0.98
Cash Flow Coverage Ratio0.19
Short Term Coverage Ratio1.75
Capital Expenditure Coverage Ratio43.75
Dividend Paid and Capex Coverage Ratio7.96

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 50.31%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.53, we discern the balance between debt and equity financing. The long-term debt to capitalization, 57.75%, and total debt to capitalization, 60.54%, ratios shed light on its capital structure. An interest coverage of 2.13 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio50.31%
Debt Equity Ratio1.53
Long Term Debt to Capitalization57.75%
Total Debt to Capitalization60.54%
Interest Coverage2.13
Cash Flow to Debt Ratio0.19
Company Equity Multiplier3.05

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 60.58, provides a glimpse into top-line earnings distributed across each share. Net income per share, 6.55, reflects the portion of profit attributed to each share. The book value per share, 59.04, represents the net asset value distributed per share, while the tangible book value per share, -54.26, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share60.58
Net Income Per Share6.55
Book Value Per Share59.04
Tangible Book Value Per Share-54.26
Shareholders Equity Per Share59.04
Interest Debt Per Share96.12
Capex Per Share-0.38

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 4.78%, indicates top-line expansion, while the gross profit growth, -10.53%, reveals profitability trends. EBIT growth, 28.70%, and operating income growth, 28.70%, offer insights into operational profitability progression. The net income growth, 293.72%, showcases bottom-line expansion, and the EPS growth, 291.52%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth4.78%
Gross Profit Growth-10.53%
EBIT Growth28.70%
Operating Income Growth28.70%
Net Income Growth293.72%
EPS Growth291.52%
EPS Diluted Growth278.36%
Weighted Average Shares Growth1.20%
Weighted Average Shares Diluted Growth15.23%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth-14.15%
Free Cash Flow Growth38.03%
10-Year Revenue Growth per Share304.82%
5-Year Revenue Growth per Share92.15%
3-Year Revenue Growth per Share42.80%
10-Year Operating CF Growth per Share254.66%
5-Year Operating CF Growth per Share29.53%
3-Year Operating CF Growth per Share6.85%
10-Year Net Income Growth per Share76.65%
5-Year Net Income Growth per Share-12.08%
3-Year Net Income Growth per Share53.03%
10-Year Shareholders Equity Growth per Share165.70%
5-Year Shareholders Equity Growth per Share28.43%
3-Year Shareholders Equity Growth per Share-10.12%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth8.33%
Inventory Growth-16.39%
Asset Growth5.15%
Book Value per Share Growth19.67%
Debt Growth0.01%
R&D Expense Growth43.90%
SGA Expenses Growth-9.57%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 12,375,136,000, captures the company's total value, considering both debt and equity. Income quality, 2.63, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 62.94%, indicates the value of non-physical assets, and capex to operating cash flow, -2.19%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value12,375,136,000
Income Quality2.63
Research and Development to Revenue22.16%
Intangibles to Total Assets62.94%
Capex to Operating Cash Flow-2.19%
Capex to Revenue-0.62%
Capex to Depreciation-3.75%
Stock-Based Compensation to Revenue5.92%
Graham Number93.31
Return on Tangible Assets9.83%
Graham Net Net-82.19
Working Capital1,727,229,000
Tangible Asset Value-3,434,172,000
Net Current Asset Value-4,392,441,000
Invested Capital2
Average Receivables678,643,500
Average Payables96,754,000
Average Inventory655,550,000
Days Sales Outstanding67
Days Payables Outstanding36
Days of Inventory On Hand209
ROIC9.70%
ROE0.11%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.89, and the price to book ratio, 1.89, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.84, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 6.61, and price to operating cash flows, 6.48, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.89
Price to Book Ratio1.89
Price to Sales Ratio1.84
Price Cash Flow Ratio6.48
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple1.91
Price Fair Value1.89
Price to Operating Cash Flow Ratio6.48
Price to Free Cash Flows Ratio6.61
Price to Tangible Book Ratio2.08
Enterprise Value to Sales3.23
Enterprise Value Over EBITDA9.53
EV to Operating Cash Flow11.33
Earnings Yield5.33%
Free Cash Flow Yield13.72%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Jazz Pharmaceuticals plc (JAZZ) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 17.064 in 2024.

What is the ticker symbol of Jazz Pharmaceuticals plc stock?

The ticker symbol of Jazz Pharmaceuticals plc stock is JAZZ.

What is company IPO date?

IPO date of Jazz Pharmaceuticals plc is 2007-06-01.

What is company current share price?

Current share price is 124.790 USD.

What is stock market cap today?

The market cap of stock today is 7780069987.000.

What is PEG ratio in 2024?

The current 0.038 is 0.038 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2800.